The Diaper Giant Paying You Nearly 5% to Wait Just Beat the Quarter
Undervalued Edge Analysis

The Diaper Giant Paying You Nearly 5% to Wait Just Beat the Quarter

Diapers, tissues, and 54 straight years of raises. One quiet earnings beat just cracked open the case, and you’re paid nearly 5% to wait.

Oct 17, 2026
Everyone Asked Who Pays for All This Computing Power, and This Firm Answered
Undervalued Edge

Everyone Asked Who Pays for All This Computing Power, and This Firm Answered

A chipmaker took about 530 megawatts of its capacity on a fifteen-year deal, with room to expand. The stock still just printed a fresh low.

Oct 16, 2026
This Biotech Won the Courtroom Fight and Still Trades Below Its Closest Peers
Undervalued Edge Analysis

This Biotech Won the Courtroom Fight and Still Trades Below Its Closest Peers

The company that won a years-long patent war just got a check from the loser. The loser’s stock soared. The winner’s barely moved.

Oct 15, 2026
This Drugmaker’s New Products Now Account for Most of Its Business
Undervalued Edge

This Drugmaker’s New Products Now Account for Most of Its Business

The drug company people worry about losing faces generic rivals as early as April 2028. The newer products already make up most of the revenue.

Oct 14, 2026
A Housing REIT With Sticky Tenants, Rising Rents, and a Valuation Gap to Match
Undervalued Edge Analysis

A Housing REIT With Sticky Tenants, Rising Rents, and a Valuation Gap to Match

A manufactured housing REIT near its 52-week low just got a Strong Buy upgrade this morning. Earnings are a week out, and the business keeps executing.

Oct 13, 2026
This Frozen Potato Giant Raised Its Outlook and Still Trades Cheap
Undervalued Edge

This Frozen Potato Giant Raised Its Outlook and Still Trades Cheap

Restaurant fries come from somewhere, and one of the biggest suppliers just beat, raised guidance, and still pays you over three percent to hold it.

Oct 12, 2026
One Pill for America’s Biggest Ignored Liver Problem and the Market Is Asleep
Undervalued Edge Analysis

One Pill for America’s Biggest Ignored Liver Problem and the Market Is Asleep

The first approved fatty-liver drug just proved it works across major genetic risk groups. Fair-value models peg it more than 40% above where it trades.

Oct 10, 2026
Wall Street Wrote the Wrong Copy on This Advertising Giant’s Future
Undervalued Edge

Wall Street Wrote the Wrong Copy on This Advertising Giant’s Future

Everyone is sure AI will gut this industry. Meanwhile, the company is cutting $1.5 billion in costs and paying you over 4% to be patient.

Oct 9, 2026
The Software Monopoly That Owns Drug Development and Is About to Own AI
Undervalued Edge Analysis

The Software Monopoly That Owns Drug Development and Is About to Own AI

A $45B life sciences monopoly raised guidance, won drugmakers, and the AI product that could reprice everything hasn’t touched the P&L yet.

Oct 8, 2026
Load more
background